Progestogen-only injectable hormonal contraceptive use should be considered in analysis of studies addressing the loss of bone mineral density in HIV-positive women.
Beksinska
Mags E
ME
Smit
Jennifer A
JA
Ramkissoon
Arthi
A
D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000209:etiology; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006679:HIV Seropositivity / Q000503:physiopathology*; D006801:Humans; D007267:Injections; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D003278:Contraceptives, Oral, Hormonal; D003692:Delayed-Action Preparations; D011372:Progestins